#ESMO26 关于 #cMET #ADCs 在经治 #EGFR WT 和 #EGFR mut 患者中的生物标志物疗效新数据：
➡️ TemabA 的 IHC MET 临界值为 10% +++
➡️ EGFR WT 的获益幅度与 MET IHC 相关，但对于
EGFRmut NSCLC 则相似
➡️ TemabA 与 Trop2 靶向 ADC 的比较疗效
@myESMO #ESMOAmbassadors
32 浏览 · 1 赞 · 0 转发 · 0 回复
Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort
https://esmocongress.esmo.orgExtended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Giannis Mountzios · x.com